TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CStone Pharmaceuticals ( (HK:2616) ) just unveiled an announcement.
CStone Pharmaceuticals announced that the European Commission has approved sugemalimab as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer (NSCLC) with specific genetic profiles. This approval expands sugemalimab’s indication to cover a broader spectrum of NSCLC, providing a new treatment option for patients in Europe. The achievement highlights CStone’s commitment to enhancing global accessibility of its therapies and addressing unmet medical needs in oncology.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals, established in 2015, is a biopharmaceutical company focused on oncology, autoimmune/inflammation, and other key disease areas. The company has launched four innovative drugs and secured approvals for 16 new drug applications across nine indications. CStone’s pipeline includes 16 promising candidates, featuring potentially first-in-class or best-in-class therapies, and is supported by a management team with comprehensive drug development expertise.
Average Trading Volume: 18,711,018
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.09B
For detailed information about 2616 stock, go to TipRanks’ Stock Analysis page.